ReviewCirculation. Heart failure2026
Hypoperfusion-Shock Continuum in Acute Decompensated Heart Failure.
Review in Circulation. Heart failure, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute decompensated heart failure is a clinical syndrome characterized by upregulation of neurohormonal compensatory mechanisms that, while intended to preserve organ perfusion as a response to reduced cardiac output, progressively exacerbate systemic congestion. Perfusion, defined by adequate oxygen delivery to the tissues, is more complex than simple cardiac output and arterial inflow, and is also significantly influenced by venous backpressure, as well as microcirculatory autoregulation. Therefore, as venous pressures continue to rise, these may ultimately contribute to hypoperfusion and, therefore, cardiogenic shock (CS). Other mechanisms, such as inflammation and increased organ capsular pressure, can contribute to further impairments in tissue oxygenation. This gradual and often clinically unrecognized deterioration from acute decompensated heart failure to heart failure-related CS (HF-CS) contrasts with acute myocardial infarction-related CS, where underlying compensatory mechanisms are more limited. Furthermore, prolonged and unrecognized hypoperfusion may further worsen HF-CS through progressive microcirculatory dysfunction with subsequent uncoupling of macrocirculation and microcirculation. At this point, normalization of macrocirculatory parameters may no longer restore tissue oxygenation. Early identification of hypoperfusion is, therefore, critical so that interventions targeting systemic hemodynamics may still improve tissue perfusion and reverse circulatory collapse. This review (1) outlines the pathophysiology of hypoperfusion in HF-CS; (2) summarizes invasive, biochemical, and imaging parameters to detect hypoperfusion; (3) phenotypes HF-CS profiles; and (4) proposes a monitoring framework for hypoperfusion in HF-CS.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.